Tags

Type your tag names separated by a space and hit enter

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
J Infect Dis. 2003 Oct 15; 188(8):1213-30.JI

Abstract

ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis, using yellow fever (YF) 17D vaccine as a vector. In a double-blind phase 2 trial, 99 adults received vaccine, placebo, or YF 17D vaccine (YF-VAX). ChimeriVax-JE was well tolerated, with no differences in adverse events between treatment groups. Viremias resulting from administration of ChimeriVax-JE and YF-VAX were of short duration and low titer; 82 (94%) of 87 subjects administered graded doses (1.8-5.8 log(10)) of ChimeriVax-JE developed neutralizing antibodies. A second dose, administered 30 days later, had no booster effect. Previous inoculation with YF did not interfere with ChimeriVax-JE, but there was a suggestion (not statistically significant) that ChimeriVax-JE interfered with YF-VAX administered 30 days later. A separate study explored immunological memory both in subjects who had received ChimeriVax-JE 9 months before and in ChimeriVax-JE-naive subjects challenged with inactivated mouse-brain vaccine (JE-VAX). Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose.

Authors+Show Affiliations

Acambis Inc, Cambridge, Massachusetts, USA. tom.monath@acambis.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

14551893

Citation

Monath, Thomas P., et al. "Chimeric Live, Attenuated Vaccine Against Japanese Encephalitis (ChimeriVax-JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge With Inactivated Japanese Encephalitis Antigen." The Journal of Infectious Diseases, vol. 188, no. 8, 2003, pp. 1213-30.
Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188(8):1213-30.
Monath, T. P., Guirakhoo, F., Nichols, R., Yoksan, S., Schrader, R., Murphy, C., Blum, P., Woodward, S., McCarthy, K., Mathis, D., Johnson, C., & Bedford, P. (2003). Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. The Journal of Infectious Diseases, 188(8), 1213-30.
Monath TP, et al. Chimeric Live, Attenuated Vaccine Against Japanese Encephalitis (ChimeriVax-JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge With Inactivated Japanese Encephalitis Antigen. J Infect Dis. 2003 Oct 15;188(8):1213-30. PubMed PMID: 14551893.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. AU - Monath,Thomas P, AU - Guirakhoo,Farshad, AU - Nichols,Richard, AU - Yoksan,Sutee, AU - Schrader,Robert, AU - Murphy,Chris, AU - Blum,Paul, AU - Woodward,Stephen, AU - McCarthy,Karen, AU - Mathis,Danell, AU - Johnson,Casey, AU - Bedford,Philip, Y1 - 2003/10/03/ PY - 2003/02/05/received PY - 2003/04/23/accepted PY - 2003/10/11/pubmed PY - 2003/12/3/medline PY - 2003/10/11/entrez SP - 1213 EP - 30 JF - The Journal of infectious diseases JO - J Infect Dis VL - 188 IS - 8 N2 - ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis, using yellow fever (YF) 17D vaccine as a vector. In a double-blind phase 2 trial, 99 adults received vaccine, placebo, or YF 17D vaccine (YF-VAX). ChimeriVax-JE was well tolerated, with no differences in adverse events between treatment groups. Viremias resulting from administration of ChimeriVax-JE and YF-VAX were of short duration and low titer; 82 (94%) of 87 subjects administered graded doses (1.8-5.8 log(10)) of ChimeriVax-JE developed neutralizing antibodies. A second dose, administered 30 days later, had no booster effect. Previous inoculation with YF did not interfere with ChimeriVax-JE, but there was a suggestion (not statistically significant) that ChimeriVax-JE interfered with YF-VAX administered 30 days later. A separate study explored immunological memory both in subjects who had received ChimeriVax-JE 9 months before and in ChimeriVax-JE-naive subjects challenged with inactivated mouse-brain vaccine (JE-VAX). Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/14551893/Chimeric_live_attenuated_vaccine_against_Japanese_encephalitis__ChimeriVax_JE_:_phase_2_clinical_trials_for_safety_and_immunogenicity_effect_of_vaccine_dose_and_schedule_and_memory_response_to_challenge_with_inactivated_Japanese_encephalitis_antigen_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/378356 DB - PRIME DP - Unbound Medicine ER -